Fragile X syndrome future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Fragile X syndrome}} Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. == References == ...") |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 3: | Line 3: | ||
{{Fragile X syndrome}} | {{Fragile X syndrome}} | ||
There are some [[medications]] under trials such as [[fenobam]] (mGLUR5 [[antagonist]]) and [[Lithium]] (mGLUR5 signaling [[inhibitor]]). | |||
== References == | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Latest revision as of 11:11, 3 January 2022
|
Fragile X syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Fragile X syndrome future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Fragile X syndrome future or investigational therapies |
|
FDA on Fragile X syndrome future or investigational therapies |
|
CDC on Fragile X syndrome future or investigational therapies |
|
Fragile X syndrome future or investigational therapies in the news |
|
Blogs on Fragile X syndrome future or investigational therapies |
|
Risk calculators and risk factors for Fragile X syndrome future or investigational therapies |
There are some medications under trials such as fenobam (mGLUR5 antagonist) and Lithium (mGLUR5 signaling inhibitor).